Cancer of Unknown Primary Diagnostics Are Advancing
Despite limited progress in prognosis, recent advancements in molecular diagnostics is transforming diagnosis of cancer of unknown primary.
Despite limited progress in prognosis, recent advancements in molecular diagnostics is transforming diagnosis of cancer of unknown primary.
A new editorial discusses findings from the COMET trial, suggesting that early-stage breast cancer may not require immediate surgery.
ClearNote Health has received approval from the New York State Department of Health for its Avantect Pancreatic Cancer Test.
The video-reporting service for in-vitro chemosensitivity testing uses real-time visual evidence to assess chemotherapy drug effectiveness.
Read MoreResearchers diagnosed leptomeningeal disease in diffuse midline gliomas by detecting H3K27M-mutant ctDNA from cerebrospinal fluid.
Read MoreOGT’s SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.
Read MoreA biomarker-based algorithm combined with a noninvasive test identifies those at risk for esophageal cancer or precancerous conditions.
Read MoreA review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read MoreResearchers developed a urine-based diagnostic kit for bladder cancer, offering a solution for early detection and monitoring at home.
Read MoreBD’s HPV Assay has been added to the ASCCP Risk-Based Management Guidelines, leveraging extended genotyping for enhanced HPV screening.
Read MoreA new test for Roche received FDA clearance as a sensitive diagnostic tool to differentiate B-cell lymphomas for improved diagnosis.
Read MoreForesight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.
Read MoreA new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.
Read MoreThe liquid biopsy test uses advanced DNA analysis and machine learning to detect six cancers at early stages with high sensitivity.
Read MoreNaveris expanded the commercial availability of its NavDx test, a non-invasive tool for detecting MRD in HPV-positive anal cancer patients.
Read MoreAI is transforming cervical cancer screening through advanced image recognition, risk prediction models, and improved accessibility.
Read MoreThe ORACLE test can predict lung cancer survival at diagnosis accurately, offering new hope for tailored treatments in stage 1 patients.
Read MoreSummary: A Mayo Clinic-led international study utilized CRISPR-Cas9 technology to classify 91% of...
Read More